The use of different HER2/neu-derived peptides (between 8 and 19 amino acids) for a breast cancer vaccine could induce an immune response in vitro and, importantly, could protect mice in a tumor challenge (Arab et al. 2018; Barati et al. 2018; Razazan et al. 2019). This evidence concerns the gene ERBB2 and breast carcinoma.